26 March 2017

Oral targeted therapies represent an increasingly important group of drugs in modern oncology. With the shift from intravenously to orally administered drugs, drug absorption often limits the full potential of these drugs.

Limited absorption and differences in metabolic capacity is a prominent cause for variability in systemic exposure and, as exposure correlates with therapeutic response, treatment outcome. Many of the oral anticancer drugs show modest bioavailability which can be majorly enhanced by food intake.
Examples of oral anticancer drugs that are much better absorbed when taken with food are abiraterone acetate and pazopanib. Our group showed that 600mg pazopanib QD taken with a continental breakfast (160-300 calories) is bio-equivalent to the licensed 800mg pazopanib QD taken fasted (presented at ASCO annual meeting 2016). This bio-equivalent lower dose results in an immediate saving of €850,­/month/patient.

Currently, the primary goal of the intervention with food, to reduce gastro-intestinal toxicity and improve patients comfort is being investigated, by Nielka van Erp, hospital pharmacist and clinical pharmacologist at Radboudumc.  Additionally the study on the effect of food on abiraterone uptake is currently ongoing.

Paragraph Volkskrant 27-03-2017

Related news items


Body composition is more important than BMI for renal cancer survival rates

11 January 2022

Body composition is important for survival rates in renal cell cancer. Research from the Radboudumc shows that low muscle quality and low organ fat are associated with poor survival. This involves different stages of renal cancer, ranging from stage I-III to stage IV.

read more

1.4 million euro to reduce hospital admissions due to medication

7 January 2022

A team of sixteen Dutch hospitals received a grant of 1.4 million euros from ZonMw. They will investigate whether they can reduce medication related hospital readmissions.

read more

Turbo Grants for four medical-technical research projects

19 October 2021

Four TURBO grants were recently awarded to new technical-medical research proposals. The grants are part of the TURBO program, a collaboration between the University of Twente (TechMed Centre) and the Radboudumc.

read more

Research into treatment for bladder pain syndrome will now be reimbursed

4 August 2021

Bladder pain syndrome, also called interstitial cystitis, is a chronic benign condition of the urinary bladder

read more

Millions of euros for study of laser treatment for glioblastoma

2 April 2021

A research group from Radboudumc and UMC Utrecht is to investigate laser treatment of a rare brain tumor, glioblastoma. 3.9 million euros has been made available for the research by Zorginstituut Nederland and ZonMw, under the auspices of the Subsidy Scheme for Promising Care.

read more

Awardees RIHS Junior Researcher round 2020

23 October 2019

Recently, RIHS held an internal call for Radboudumc junior researcher (PhD) positions. This year 6 positions have been awarded.

read more